Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (941-950 of 1,482) with videos related to

Pageof 149
Sort By:
Cancer|June 25, 2021
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemiaKapil Saxena, Shelley M Herbrich, Naveen Pemmaraju, et al.
Blood Cancer Discovery|April 14, 2026
Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trialJayastu Senapati, Hagop M Kantarjian, Edward Ayoub, et al.
Leukemia|April 27, 2026
Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adultsGabriel Aleixo, HeeJin Cheon, Jiayin Zheng, et al.
The Lancet. Haematology|May 15, 2023
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Nicholas J Short, Jayastu Senapati, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
Blood Advances|March 24, 2019
<i>NPM1</i> mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, et al.
The Lancet. Oncology|October 4, 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Haematologica|March 23, 2023
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)Guillaume Richard-Carpentier, Caitlin R Rausch, Koji Sasaki, et al.
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Blood Advances|April 19, 2024
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndromeCourtney D DiNardo, Gail J Roboz, Justin M Watts, et al.
Pageof 149

Showing results (941-950 of 1,482) with videos related to

Sort By:
Pageof 149
Cancer|June 25, 2021
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemiaKapil Saxena, Shelley M Herbrich, Naveen Pemmaraju, et al.
Blood Cancer Discovery|April 14, 2026
Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trialJayastu Senapati, Hagop M Kantarjian, Edward Ayoub, et al.
Leukemia|April 27, 2026
Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adultsGabriel Aleixo, HeeJin Cheon, Jiayin Zheng, et al.
The Lancet. Haematology|May 15, 2023
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Nicholas J Short, Jayastu Senapati, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
Blood Advances|March 24, 2019
<i>NPM1</i> mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, et al.
The Lancet. Oncology|October 4, 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Haematologica|March 23, 2023
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)Guillaume Richard-Carpentier, Caitlin R Rausch, Koji Sasaki, et al.
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Blood Advances|April 19, 2024
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndromeCourtney D DiNardo, Gail J Roboz, Justin M Watts, et al.
Pageof 149